Bicycle Therapeutics (BCYC) Competitors $8.56 +0.35 (+4.26%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$9.02 +0.47 (+5.43%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. TWST, MTSR, VCEL, SDGR, DNLI, MIRM, TARS, GMTX, BEAM, and NAMSShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Twist Bioscience (TWST), Metsera (MTSR), Vericel (VCEL), Schrödinger (SDGR), Denali Therapeutics (DNLI), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Beam Therapeutics (BEAM), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Twist Bioscience Metsera Vericel Schrödinger Denali Therapeutics Mirum Pharmaceuticals Tarsus Pharmaceuticals Gemini Therapeutics Beam Therapeutics NewAmsterdam Pharma Twist Bioscience (NASDAQ:TWST) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Do analysts rate TWST or BCYC? Twist Bioscience presently has a consensus price target of $52.80, indicating a potential upside of 37.79%. Bicycle Therapeutics has a consensus price target of $29.14, indicating a potential upside of 240.45%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility and risk, TWST or BCYC? Twist Bioscience has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Do insiders & institutionals have more ownership in TWST or BCYC? 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 3.0% of Twist Bioscience shares are owned by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to TWST or BCYC? In the previous week, Twist Bioscience had 7 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 13 mentions for Twist Bioscience and 6 mentions for Bicycle Therapeutics. Twist Bioscience's average media sentiment score of 1.28 beat Bicycle Therapeutics' score of 1.03 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TWST or BCYC more profitable? Twist Bioscience has a net margin of -59.76% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-59.76% -32.69% -25.25% Bicycle Therapeutics -450.64%-27.35%-20.81% Does the MarketBeat Community believe in TWST or BCYC? Bicycle Therapeutics received 37 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 70.65% of users gave Bicycle Therapeutics an outperform vote while only 58.99% of users gave Twist Bioscience an outperform vote. CompanyUnderperformOutperformTwist BioscienceOutperform Votes10558.99% Underperform Votes7341.01% Bicycle TherapeuticsOutperform Votes14270.65% Underperform Votes5929.35% Which has preferable valuation and earnings, TWST or BCYC? Bicycle Therapeutics has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$330.19M6.92-$208.73M-$3.38-11.34Bicycle Therapeutics$35.28M16.79-$180.66M-$2.88-2.97 SummaryBicycle Therapeutics beats Twist Bioscience on 12 of the 18 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$592.37M$6.89B$5.57B$7.83BDividend YieldN/A3.06%5.11%4.21%P/E Ratio-2.607.4422.4418.48Price / Sales16.79242.73394.10103.59Price / CashN/A65.8538.1834.62Price / Book0.696.516.774.25Net Income-$180.66M$143.21M$3.22B$248.23M7 Day Performance-1.27%3.95%3.25%3.29%1 Month Performance-4.57%0.34%0.01%2.42%1 Year Performance-63.50%2.58%18.00%5.54% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.0388 of 5 stars$8.56+4.3%$29.14+240.5%-63.5%$592.37M$35.28M-2.60240Earnings ReportShort Interest ↓Positive NewsTWSTTwist Bioscience3.6172 of 5 stars$34.56-6.1%$52.80+52.8%+22.7%$2.06B$330.19M-10.22990Upcoming EarningsPositive NewsGap DownMTSRMetseraN/A$19.51-0.3%$47.00+140.9%N/A$2.05BN/A0.0081News CoverageHigh Trading VolumeVCELVericel2.3089 of 5 stars$40.87-0.9%$60.86+48.9%-17.1%$2.05B$237.22M681.28300Upcoming EarningsNews CoveragePositive NewsSDGRSchrödinger2.2801 of 5 stars$26.19+1.7%$33.00+26.0%+5.1%$1.91B$207.54M-11.19790Upcoming EarningsGap DownDNLIDenali Therapeutics4.1568 of 5 stars$13.15+3.2%$37.57+185.7%+7.8%$1.91B$330.53M-4.76430Upcoming EarningsPositive NewsMIRMMirum Pharmaceuticals4.2437 of 5 stars$38.39-1.8%$58.20+51.6%+73.0%$1.90B$336.89M-19.00140Upcoming EarningsNews CoveragePositive NewsTARSTarsus Pharmaceuticals1.3696 of 5 stars$48.51-1.5%$63.67+31.2%+65.2%$1.86B$182.95M-12.7350Upcoming EarningsPositive NewsGMTXGemini TherapeuticsN/A$42.17+2.8%N/A+66.7%$1.83BN/A-42.1730BEAMBeam Therapeutics3.0263 of 5 stars$18.24+7.3%$49.45+171.1%-6.1%$1.82B$63.52M-10.36510Upcoming EarningsShort Interest ↑High Trading VolumeNAMSNewAmsterdam Pharma3.1884 of 5 stars$16.26-0.5%$43.33+166.5%-12.3%$1.79B$45.56M-6.254Positive News Related Companies and Tools Related Companies Twist Bioscience Competitors Metsera Competitors Vericel Competitors Schrödinger Competitors Denali Therapeutics Competitors Mirum Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Gemini Therapeutics Competitors Beam Therapeutics Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCYC Stock Free BCYC Stock Alerts